InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by HERVE AFFAGARD, Chief Executive Officer. Insider active across 1 companies, notably MAAT PHARMA. In total, 10 filings have been published. Total volume traded: €80k. The latest transaction was disclosed on 18 November 2025 — Acquisition. Regulator: AMF. The full history is accessible without signup.
Declarations10 total
€9,0482,600 shares@ €3.480.0081% mcap5.8% of flow
ActionEuronext Paris
2025DD1071415·
Ideal exit: 15 Aug 2026 (T+270)
€1,496430 shares@ €3.480.0013% mcap1.0% of flow
ActionEuronext Paris
2025DD1070840·
Ideal exit: 15 Aug 2026 (T+270)
€35,0004,375 shares@ €8.000.032% mcap22.6% of flow
ActionEuronext Paris
2024DD967653·
Ideal exit: 11 Feb 2025 (T+270)
€14,9942,940 shares@ €5.100.014% mcap9.7% of flow
ActionEuronext Paris
2023DD944150·
Ideal exit: 17 Sept 2024 (T+270)
€3,050500 shares@ €6.100.0027% mcap2.0% of flow
ActionEuronext Paris
2023DD930462·
Ideal exit: 23 Jun 2024 (T+270)
€50,0006,250 shares@ €8.0032.3% of flow
ActionEuronext Paris
2023DD885951·
€3,075300 shares@ €10.250.0028% mcap2.0% of flow
ActionEuronext Paris
2022DD851054·
Ideal exit: 2 Apr 2023 (T+270)
€24,5431,818 shares@ €13.5015.8% of flow
ActionEuronext Paris
2021DD798423·
€5,496405 shares@ €13.570.0049% mcap3.5% of flow
ActionEuronext Paris
2021DD798428·
Ideal exit: 12 Aug 2022 (T+270)
€8,181606 shares@ €13.500.0074% mcap5.3% of flow
ActionEuronext Paris
2021DD798713·
Ideal exit: 25 Jul 2022 (T+270)
10 of 10 declarations
About HERVE AFFAGARD
Hervé Affagard is the Chief Executive Officer and co-founder of MaaT Pharma, a French biotechnology company focused on microbiome-based therapies. He represents the profile of a founder-executive who combines scientific ambition, industrial discipline, and operational execution in one of the most demanding areas of healthcare innovation. According to the company’s official biography, he has led MaaT Pharma since its initial concept in 2013 and has played a central role in building the microbiome ecosystem in France and across Europe. Before dedicating himself to MaaT Pharma, Affagard began his career in IT within the steel industry and later spent more than fifteen years as an intrapreneur in healthcare. That background gave him a strong understanding of product development, transformation, and scaling in regulated environments. MaaT Pharma describes him as an engineer with an MBA, a combination that reflects both technical rigor and strategic thinking. At MaaT Pharma, he co-founded the company with Dr. Joël Doré, a leading microbiome expert, with the aim of developing innovative medicines to restore microbiome balance in severe medical settings, including oncology and intensive treatment contexts. The company’s progression into clinical development and its listing on Euronext Paris reflect a leadership approach centered on scientific validation, financing access, and the creation of a credible industrial player in biotherapeutics. In January 2022, Affagard was also elected President of Alliance Promotion Microbiote, underscoring his influence beyond his corporate role. This position highlights his broader contribution to the development of the microbiome sector in France, with a focus on ecosystem building, stakeholder awareness, and the acceleration of therapeutic innovation. Overall, his career is defined by turning a scientific insight into an industrial and clinical venture, then helping transform that venture into a listed company with international ambitions. The Entrepreneur in Health award he received from France Biotech in 2016 further recognized his role in advancing a new therapeutic field in France.
